Celgene Reports First Quarter 2015 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Celgene Reports First Quarter 2015 Operating and Financial Results
April 30, 2015 2:57 PM EDT
BMO Capital analyst Jim Birchenough reiterated his Outperform rating and $163 price target on Celgene (NASDAQ: CELG) following Q1 result which he called "solid" despite seasonal headwinds.
Birchenough commented, "We are reiterating our Outperform rating on the shares of CELG following review of 1Q15... More
April 30, 2015 7:31 AM EDT
Celgene (NASDAQ: CELG) reported Q1 EPS of $1.07, $0.01 better than the analyst estimate of $1.06. Revenue for the quarter came in at $2.08 billion versus the consensus estimate of $2.11 billion.
Product and Pipeline Updates
Hematology
REVLIMID®: In February, the U.S. Food and Drug Administration expanded the approved indication for REVLIMID® to include the treatment of patients with newly diagnosed multiple myeloma (NDMM), in combination with dexamethasone. Also in February, the European Commission (EC) approved REVLIMID® for the treatment of adult patients with previously untreated multiple... More
